E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis

CB Vos, AM Cleton-Jansen, G Berx… - British journal of …, 1997 - nature.com
CB Vos, AM Cleton-Jansen, G Berx, WJF De Leeuw, NT Ter Haar, F Van Roy, CJ Cornelisse…
British journal of cancer, 1997nature.com
In breast cancer, inactivating point mutations in the E-cadherin gene are frequently found in
invasive lobular carcinoma (ILC) but never in invasive ductal carcinoma (IDC). Lobular
carcinoma in situ (LCIS) adjacent to ILC has previously been shown to lack E-cadherin
expression, but whether LCIS without adjacent invasive carcinoma also lacks E-cadherin
expression and whether the gene mutations present in ILC are already present in LCIS is
not known. We report here that E-cadherin expression is absent in six cases of LCIS and …
Abstract
In breast cancer, inactivating point mutations in the E-cadherin gene are frequently found in invasive lobular carcinoma (ILC) but never in invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) adjacent to ILC has previously been shown to lack E-cadherin expression, but whether LCIS without adjacent invasive carcinoma also lacks E-cadherin expression and whether the gene mutations present in ILC are already present in LCIS is not known. We report here that E-cadherin expression is absent in six cases of LCIS and present in 150 cases of ductal carcinoma in situ (DCIS), both without an adjacent invasive component. Furthermore, using mutation analysis, we could demonstrate the presence of the same truncating mutations and loss of heterozygosity (LOH) of the wild-type E-cadherin in the LCIS component and in the adjacent ILC. Our results indicate that E-cadherin is a very early target gene in lobular breast carcinogenesis and plays a tumour-suppressive role, additional to the previously suggested invasion-suppressive role.
nature.com